Revised forecast
Fiscal year ending April 2026 · Full yearPrevious forecast published 11 September 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The revision reflects higher prescription prices resulting from prescriptions for high-priced pharmaceuticals in the pharmacy business, the steady number of prescriptions, steady progress in the PMI of the Sakura Pharmacy Group, and an increased outlook for future tax burden reductions, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥646,000 million → ¥647,500 million（0.2％） |
| Operating profit | ¥28,300 million → ¥29,500 million（4.2％） |
| Ordinary income | ¥26,500 million → ¥28,000 million（5.7％） |
| Profit attributable to owners of the parent | ¥13,500 million → ¥17,000 million（25.9％） |
| Net income per share | 384.91 yen → 484.08 yen |
| Fiscal Period Covered | Fiscal year ending April 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 11 September 2025 |
| Previous-period results | Fiscal year ended April 2025: net sales of ¥456,804 million, EBITDA of ¥31,040 million, operating profit of ¥16,871 million, ordinary profit of ¥18,080 million, net income attributable to owners of the parent of ¥9,261 million, and net income per share of ¥264.32 |
| Reason for the revision | The revision reflects higher prescription prices resulting from prescriptions for high-priced pharmaceuticals in the pharmacy business, the steady number of prescriptions, steady progress in the PMI of the Sakura Pharmacy Group, and an increased outlook for future tax burden reductions, among other factors. |
| Dividend forecast revision | The year-end dividend forecast has been increased from ¥80.00 per share to ¥100.00 per share, an increase of ¥20.00. The annual dividend has also been increased from ¥80.00 per share to ¥100.00 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The revision reflects higher prescription prices resulting from prescriptions for high-priced pharmaceuticals in the pharmacy business, the steady number of prescriptions, steady progress in the post-merger integration (PMI) of the Sakura Pharmacy Group, which joined the Group on 1 August 2025, and an increased outlook for future tax burden reductions. The dividend was increased in accordance with the shareholder return policy because full-year net income attributable to owners of the parent is expected to exceed the previous forecast.